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Clofazimine and clarithromycin are used to treat leprosy and infections caused by Mycobacterium 
avium complex. Little data on the toxicity of co-administration of these two drugs are available. Here 
we evaluated the potential adverse effects of polytherapy with these two drugs in male Wistar rats by 
determining WBCs counts and other blood cell counts, neutrophilic phagocytosis, and burst oxidative, by 
flow cytometry. We observed an increase in WBCs, in multiple-dose regimens, and in polymorphonuclear 
cells, in both single- clarithromycin only and multiple dose regimens. We also observed a reduction in 
mononuclear cell counts in single and multiple doses. The drugs seem to reverse the mononuclear and 
polymorphonuclear cell ratio. An increase in oxidative burst was observed in animals treated with the 
drugs administered either individually or combined. In conclusion, clofazimine and clarithromycin 
change WBCs counts. Our results may contribute for a better understanding of the mechanisms related 
to the effects of co-administrating the two drugs. 
Uniterms: Clofazimine/adverse effects/experimental study. Clarithromycin/adverse effects/experimental 
study. Leprosy/treatment. Mycobacterium avium/infections/treatment. Leukocytes. Phagocytosis. 
Oxidative burst.
Clofazimina e laritromicina são utilizadas no tratamento da hanseníase e em infecções causadas pelo 
complexo Mycobacterium avium. Devido à escassez de dados sobre a toxicidade de esquemas terapêuticos 
que associam estes fármacos, este estudo teve por objetivo avaliar os efeitos adversos desta terapia, em 
ratos machos Wistar, por meio da determinação da contagem global e específica de leucócitos e ensaios 
de fagocitose e burst oxidativo de neutrófilos por citometria de fluxo. Houve aumento do número de 
leucócitos (dose múltipla) e de células polimorfonucleares (doses única e múltipla) nos grupos tratados 
com claritromicina em monoterapia ou associada à clofazimina e redução das células mononucleares, em 
doses única e múltipla, nos mesmos grupos. Os fármacos parecem inverter a proporção entre células mono 
e polimorfonucleares. Observou-se aumento do burst oxidativo nos animais tratados com os fármacos 
isolados ou associados. Concluindo, clofazimina e claritromicina provocam alterações leucocitárias e 
os resultados podem contribuir para melhor entendimento dos mecanismos relacionados aos efeitos da 
administração dos fármacos em associação.
Unitermos: Clofazimina/efeitos adversos/estudo experimental. Claritromicina/efeitos adversos/
estudo experimental. Hanseníase/tratamento. Mycobacterium avium/infecções/tratamento. Leucócitos. 
Fagocitose. Burst oxidativo.
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INTRODUCTION
Clofazimine (CFZ) and clarithromycin (CRT) are 
antimicrobial drugs used for the treatment of diseases such 
as leprosy and tuberculosis, and for infections caused by 
the Mycobacterium avium complex in AIDS (acquired im-
mune deficiency syndrome) patients (Ji et al., 1993; Field, 
Cowie, 2003; Katoch, 2004). Because these two drugs are 
used in polytherapy regimens it is important to investigate 
if their association results in adverse effects.
Established Mycobacterium avium infections are 
treated with a combination of clarithromycin and etham-
butol, unless the isolate shows resistance to macrolides. 
Although the association between clarithromycin and 
ethambutol is the first choice for the treatment of dis-
seminated infections, the alternatives include the use of 
azitromicin, ciprofloxacine, clofazimine, and amikacin. 
Co-administration of clofazimine and clarithromycin is 
effective and well-tolerated when used to treat infections 
caused by Mycobacterium avium.
Leprosy is a chronic infectious disease caused by 
Mycobacterium leprae. The disease is still current, es-
pecially in undeveloped and developing countries. The 
World Health Organization indicates the use of polyche-
motherapy for the treatment of Leprosy (Declercq, 2001). 
The treatment combines dapsone, clofazimine, and rifam-
picin. Clofazimine and clarithromycin have also shown to 
be effective (Chambers, 2007).
Although a number of studies have investigated the 
role of these two drugs over the modulation of inflamma-
tory responses, including the production of reactive oxy-
gen species (ROS) by phagocytes (Umeki, 1993; Lemke, 
1995; Shirai et al., 1995; Wenisch et al., 1995; Wenisch et 
al., 1996; Abdelghaffar et al., 1997; Kadota et al., 1998; 
Kadir et al., 2000; Abdelghaffar et al., 2002; Jain et al., 
2002; Sugihara et al., 2003; Tamaoki et al., 2004; Ishida 
et al., 2007; Yano et al., 2011), none have evaluated the 
effects of co-administration of the two drugs.
It is known that clofazimine stimulates the produc-
tion of oxidants such as superoxide radical anion, which 
helps defend the organism against intracellular pathogens 
(Lemke, 1995; Yano et al., 2011). Macrolide antibiotics, 
including clarithromycin, act as immunomodulators in 
chronic inflammatory diseases of the respiratory tract by 
inhibiting the production of inflammatory cytokines. They 
also inhibit the mRNA of the transcription factors associ-
ated to these cytokines (Ishida et al., 2007). Additionally, 
due to its anti-inflammatory effects, clarithromycin blocks 
the formation of adhesion molecules necessary for the 
migration of the neutrophils to the body tissues (Tamaoki 
et al., 2004).
In a previous study (Paina et al., 2008) we observed 
a number of hematological, hemostatic, and biochemical 
changes in rats receiving monotherapy of either clofazi-
mine or clarithromycin. However, no study has investi-
gated the occurrence of potential changes when these two 
drugs are co-administered. In this study we investigated 
the effects that clofazimine and clarithromycin, either 
combined or separately, have over the number of leuco-
cytes, mononuclear and polymorphonuclear cells and on 
the oxidative burst and neutrophilic phagocytosis in rats.
MATHERIAL AND METHODS
A total of 83 young Wistar SPF male rats (specific 
pathogen free) weighing between 240 and 260 g were 
provided by the Biotério II of the School of Pharmaceuti-
cal Sciences of University of São Paulo in Ribeirão Preto. 
The study here presented was approved by the Ethical 
Committee of the University of São Paulo (USP), Ribeirão 
Preto campus.
A total of 83 animals were separated in 8 groups as 
follows: the CFZ-single group (N=7) was treated with 
a single dose of 100 mg of clofazimine per kg of body 
weight; the CRT-single group (N=7) was treated with a 
single dose of 100 mg of clarithromycin per kg of body 
weight; the CFZ + CRT-single group (N=7) was treated 
with a single dose of 100 mg of each drug (clofazimine 
and clarithromycin) per kg of body weight. Blood collec-
tion was performed two hours after administration; the 
CFZ-multiple group (N=13) was treated with 100 mg of 
clofazimine per kg of body weight every 12 hours for 4 
days; the CRT-multiple group (N=16) was treated with 
100 mg of clarithromycin per kg of body weight every 
12 hours for 4 days; and the CFZ + CRT-multiple group 
(N=15) was treated with 100 mg of each drug (clofazimine 
and clarithromycin) per kg of body weight every 12 hours 
for 4 days. Blood collection was conducted 12 hours after 
the last dose. Two control groups that received dimethyl-
sufoxide (DMSO) in a single-dose regimen (N=7) or in a 
multiple-dose regimen (N=11) were also included in the 
study. The animals were euthanized by cervical dislocation 
after material collection.
Reagents
Phorbol myristate acetate (PMA) and n-formyl-
methionyl-leucyl-phenylalanine (fMLP) were obtained 
from the kit Burst Test (ORPEGEN Pharma, Heidelberg, 
Germany); dihydrorhodamine (DHR) and fluorescein 
isothiocyanate (FITC) were obtained from Sigma-Adrich 
(St. Louis, USA).
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Methods
·	 Manual WBC count was done using May-Grünwald/
Giemsa from total blood in EDTA, using optical 
microscope.
·	 Neutrophilic oxidative burst assay of peripheral 
blood, either or not stimulated by PMA or fMLP, 
was done according to the method described by 
Richardson et al. (1998): fluorescence intensity was 
measured by flow cytometry (FacScan®, Becton-
-Dickinson, Bioscience, San Jose, USA). We worked 
with three different tubes containing 100 µL of 
heparinized blood. To each tube we added one of 
the following: 25 µL of PMA 8.1 µM, or 25 µL of 
fMLP 8.1 µM, or 25 µL of PBS. The blank control 
had 25 µL of PBS only. All tubes were incubated at 
37 ºC for 15 minutes. Next, 25 µL of DHR 30 µg/mL 
were added to both stimulated and unstimulated cells 
while 25 µL of PBS were added to the white tube. 
The tubes were then incubated at 37ºC for 5 minutes. 
Erythrocytes were lysed with 1 mL of lyse solution 
(BD FACSTM Lysing Solution, Becton Dickinson) 
for 10 minutes at room temperature. Next, we added 
1 mL of PBS to the tubes. Cells were washed twice 
in PBS at a temperature between 4 and 8 °C, 400 g, 
5 min, and resuspended with 1 mL of 1% parafor-
maldehyde in PBS. Reading was done with FACS, 
using argon-ion laser blue-green light at 488 nm; 
10,000 events were collected per sample. 
·	 Neutrophilic phagocytosis assay: fluorescence in-
tensity was measured by FACS (FacScan®, Becton 
Dickinson, Bioscience, San Jose, USA). A total of 
100 μL of total heparinized blood was incubated 
with 100 μL of FITC-labeled Escherichia coli for 10 
minutes at 37°C. Addition of 100 μL of quenching 
solution (trypan blue 4 mg/mL in 0.02 M sodium ci-
trate buffer) suppressed the florescence of non-pha-
gocytized bacteria. Leucocytes were washed twice 
in PBS at 4-8 °C, centrifuged at 250 g for 5 min, 
and erythrocytes were lysed with lysing solution 
(BD FACSTM Lysing Solution, Becton Dickinson) 
for 10 minutes at room temperature. Samples were 
once again washed at 4–8°C, centrifuged at 250 g 
for 5 min and resuspended in 500 µL of PBS and 
submitted to FACS argon-ion laser blue-green light 
at 488 nm; 10,000 events were collected per event.
Statistical analysis
We used the GraphPad Prism® program version 5.0 
for the non-parametric Kruskal-Wallis test followed by 
the Dunns post-test and ANOVA followed by Bonferroni 
post-test. Significant levels were set as p<0.05.
RESULTS
Effects of clofazimine and clarithromycin, 
combined and separated, over the number 
of leucocytes, mononuclear cells, and 
polymorphonuclear cells of the peripheral blood
WBC counts in rats treated with the drugs and with 
the control (DMSO) in single-dose regimens presented 
no statistical difference among groups (data not shown). 
For multiple-doses regimens, animals treated with clar-
ithromycin and with co-administration of the two drugs 
showed an increased number of WBCs when compared 
to the control group (Figure 1A).
Figure 1B and 1C shows the number of mononuclear 
cells in rats treated with single- and multiple-dose regi-
mens. We observed a reduction in cell counts in animals 
treated with clarithromycin and with co-administration 
of the two drugs, when compared to the control group 
and to the group treated with clofazimine only, either in 
single-dose regimens or in multiple doses. Although no 
statistical difference was observed among the groups re-
ceiving single doses, as indicated by the Dunns post-test, 
the difference could be seen through the median of the 
samples (p<0.05).
There was an increase in polymorphonuclear cell 
counts in all cases, when compared to controls (Figure 
1D and 1E).
Effects of clofazimine and clarithromycin, 
combined and separated, over oxidative burst and 
neutrophilic phagocytosis
In multiple-dose regimens the oxidative burst was 
more characterized in the groups stimulated with PMA 
when compared to those non-stimulated or stimulated 
with fMLP. Additionally, animals treated with CFZ + 
CRT showed a higher oxidative burst activity when com-
pared to controls or to animals treated with one drug only 
(p<0.0001) (Figure 1F). No statistical difference was 
observed among groups for the neutrophilic phagocytosis 
(data not shown).
DISCUSSION
Studies on drug effects are important for optimiza-
tion of therapies so patients can receive treatments that 
are more effective and safer. The choice of the drugs dose 
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FIGURE 1 - Quantitative and functional rats WBC treated with clofazimine (CFZ), clarithromycin (CRT) and the combination 
of the two drugs at a dose of 100 mg/kg, compared with the control DMSO. A: WBC counts in multiple dose regime (Kruskal-
Wallis test followed by Dunns multiple comparison, * p <0.05 and ** p <0.001 compared to DMSO), B: Mononuclear cell count 
in single-dose regimen (Kruskal-Wallis, p <0.05), C: Number of mononuclear cells in multiple-dose regimen (Kruskal-Wallis test 
followed by Dunns multiple comparisons, ** p <0.001 For DMSO and CFZ), D: Polymorphonuclear cell counts in single-dose 
regimen (Kruskal-Wallis test followed by Dunns multiple comparison, * p <0.05 for DMSO), E: Polymorphonuclear cell counts 
under multiple-dose regimens (Kruskal-Wallis test followed by Dunns multiple comparisons, ** p <0.001 compared to CFZ, *** 
p <0.0001 compared to DMSO, * p <0.05 for CFZ, *** p <0.0001 compared to DMSO), F: Mean fluorescence intensity produced 
by the oxidative burst of neutrophils in multiple-dose regimen (ANOVA test. CFZ: *** p < 0.001 compared to control and fMLP; 
CRT: *** p <0.001 compared to control and fMLP; CFZ + CRT: *** p <0.001 compared to control and fMLP).
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used in this work was based on the highest dose used for 
human treatment.
We observed that CRT-multiple, as well as 
CFZ+CRT-multiple, increased WBC counts. Although 
no statistical significance was observed, CFZ-multiple 
presented higher median values when compared to the 
DMSO control group (not shown). Interesting, among 
the adverse effects associated to erythromycin, which is 
a structural analogue of clarithromycin, are leukocytosis 
and eosinophilia. Nevertheless, it has been reported that 
all adverse effects disappear within a few days after the 
treatment is over (Chambers, 2007).
A reduction of mononuclear count was observed in 
rats receiving CRT-single or CFZ + CRT-single. Although 
the Dunn’s post-test revealed no statistical difference 
among groups, differences in the median values (p<0.05) 
were observed when the Kruskal-Wallis test was applied 
(Figure 1B). Mononuclear cell count was also reduced 
in both CRT-multiple and CFZ + CRT-multiple, but a 
significant reduction was observed only when the two 
drugs were combined (CFZ + CRT-multiple) (Figure 1C). 
Polymorphonuclear cells presented opposite behaviors 
in treated groups when compared to control. In this case 
an augmentation in cell counts in the CFZ, CRT, and 
CFZ+CRT groups in both regimens was observed (Figure 
1D and 1E). We noticed a reduction in mononuclear cell 
counts and an increase in polymorphonuclear cell counts 
only in the CRT and CFZ+CRT groups, indicating that 
CRT is the drug responsible for inverting the cell ratio. 
This may be due to a mobilization of the marginal neutro-
philic pool, as the time-lapse between drug (or control) 
injections and sample collection was of two hours only. 
This effect was more pronounced in multi-dose regimens. 
In this case, the mechanism may be related to the drug’s 
antimicrobial and anti-inflammatory actions, which also 
affect the neutrophilic functional response.
Previous studies have reported a reduction in lym-
phocyte counts in the broncho-alveolar wash of patients 
of chronic respiratory diseases who used macrolides for 
long periods. The effects of macrolides over human lym-
phocytes isolated from peripheral blood are also associ-
ated with apoptosis induction, which may be related to the 
anti-inflammatory actions of clarithromycin, azitromicin, 
and josamicin (Ishimatsu et al., 2004). It has also been 
shown that clarithromycin may reduce lymphocyte counts 
in the lungs of rats with respiratory infection caused by 
Pseudomonas aeruginosa (Mukae et al., 1995). Similar re-
sults were observed in studies on lung diseases in humans 
(Yanagihara et al., 1997).
The oxidative burst analysis in rats’ neutrophils 
treated with multiple-dose regimens (Figure 1F), revealed 
an increase of activity in all groups, regardless of the num-
ber of drugs used (whether one drug or the two drugs com-
bined) when stimulated with PMA, as compared to those 
stimulated with fMLP. This may be explained by the fact 
that a few receptors for fMLP are available on neutrophils 
(Vuorte et al., 1996). Additionally, PMA is a structural 
analog of the diacylglicerol and a potent and lipophilic 
stimulant that crosses the cell membrane with ease where 
it activates the oxidative burst through the kinase C protein 
(PKC) (Sheppard et al., 2005). The increase in oxidative 
bust activity followed the CFZ < CRT < CFZ + CRT order.
In this study we observed an increase in oxidative 
burst in rats’ neutrophils treated with clofazimine in multi-
dose regimen, which agrees with previous studies showing 
the occurrence of ROS as a mechanism of antimicrobial 
action and protection against infections (Lemke, 1995; 
Yano et al., 2011). However, it has been shown that mac-
rolides inhibit production of neutrophilic ROS (Umeki, 
1993; Abdelghaffar et al., 1997; Kadota et al., 1998; Kadir 
et al., 2000; Abdelghaffar et al., 2002; Jain et al., 2002; 
Sugihara et al., 2003). This apparent disparity in findings 
may be explained by the fact that in our study the neutro-
philic oxidative burst analysis was done in ex-vivo and 
with total blood, whereas in previous studies this analysis 
was done in vitro (Umeki, 1993; Abdelghaffar et al., 1997; 
Kadota et al., 1998; Kadir et al., 2000; Abdelghaffar et al., 
2002; Jain et al., 2002; Sugihara et al., 2003). It has been 
suggested that difficulties associated to cell isolation may 
affect the results because when the phagocyte is isolated 
from the total blood any factor necessary for its modula-
tion may be missing (Labro, 2000). By using total blood 
we avoided separating the granulocytes and precluded 
the cellular activation that may occur due to the separa-
tion. Also to be considered are the different functional 
capacities of several pools of granulocytes and monocytes/
macrophages. Finally, the use of ex-vivo models allows 
better accuracy and reproducibility (Wenisch et al., 1996).
Studies reporting inhibition of neutrophilic oxidative 
burst by macrolides (Umeki, 1993; Abdelghaffar et al., 
1997; Kadota et al., 1998; Kadir et al., 2000; Abdelghaf-
far et al., 2002; Jain et al., 2002; Sugihara et al., 2003) 
used techniques like cytochrome-c reduction or chemi-
luminescence of luminol and lucigenin, which evaluate 
ROS release in the extracellular environment. FACS 
evaluates intracellular ROS. Of note is the fact that the 
dihydrorhodamine 123 (DHR) used to detect ROS binds 
to cellular and mitochondrial membranes, thus it detects an 
intracellular signal that responds to the presence of H2O2, 
specifically (Elbim, Lizard, 2009).
In studies that used FACS to evaluate the effects of 
antimicrobial treatments on neutrophilic burst oxidative 
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activity and phagocytosis (Wenisch et al., 1995; Wenisch 
et al., 1996), no changes in ROS production were observed 
in patients who used clarithromycin. In a different study, 
an increase in neutrophilic oxidative burst activity was 
observed (Shirai et al., 1995). Methods using chemilumi-
nesence and others that use nitroblue tetrazolium (NBT) 
reduction show great intra and inter variation and are 
considered of low accuracy (Wenisch et al., 1996).
Another difference between in vitro and ex-vivo 
analysis regards the plasmatic and/or intracellular con-
centration of the macrolides and the phagocytosis capacity 
of polymorphonuclear cells and ROS production. In the 
studies mentioned earlier, authors (Umeki, 1993; Ab-
delghaffar et al., 1997; Kadota et al., 1998; Kadir et al., 
2000; Abdelghaffar et al., 2002; Jain et al., 2002; Sugihara 
et al., 2003) could control the concentration of the drug 
responsible for inhibiting ROS production by neutrophils, 
as the drugs were directly incubated with the cells. It is 
known that the level of intracellular concentration does 
not necessarily relate with the intracellular drug activity 
and that the drug penetration and intracellular localization 
should also be considered (Wenisch et al., 1996).
Several factors affect antibiotics activity in vivo. 
The applied dose may affect the susceptibility of the 
infectious agent, and the concentration it reaches in the 
plasma and in other body fluids and tissues. Most impor-
tant is the concentration it reaches in the infection site 
(Bakker-Woudenberg et al., 2005). Indeed, a previous 
report revealed that the increase or reduction of drug 
concentration in phagocytes is directly proportional to 
plasma concentrations (Amsden, 2001). This work also 
points out that in vitro susceptibility studies do not reflect 
the actual antibiotic concentrations to which he pathogen 
is exposed at the infection site, where it is phagocytosed by 
the immune system. Another problem of in vitro minimum 
inhibitory concentration determinations is that such tests 
do not consider the inherent activity of the plasma, which 
can cause changes in the final concentration values.
Another issue on the different findings between 
ex-vivo and in vitro studies regards the mononuclear and 
polymorphonuclear cell ratio. The increased number of 
polymorphonuclear leukocytes may explain the in-
creased neutrophils-mediated oxidative burst. All the 
aforementioned issues may be related to controversial 
data previously reported regarding the effects of clar-
ithromycin on neutrophilic oxidative burst (Umeki, 1993; 
Abdelghaffar et al., 1997; Kadota et al., 1998; Kadir et al., 
2000; Abdelghaffar et al., 2002; Jain et al., 2002; Sugihara 
et al., 2003).
Cytokine secretions such as interleukins, growth 
factors, interferons, and tumor necrosis factor, are made by 
leukocytes and other cell types. They provide both stimula-
tion and inhibition of hematopoiesis (Socolovsky, 1998) 
and are important mediators of inflammation. Macrolide 
antibiotics exert anti-inflammatory effects by inhibiting 
the production of these cytokines through the modulation 
of the nuclear factor kB (NF-kB), a transcription factor for 
genes that encode pro-inflammatory cytokines such as IL-
1, IL-6, IL-8, and TNF-a. Additionally, these antibiotics 
also inhibit the production of prostaglandin E2, and neu-
trophil chemotaxis and elastase activity. Clarithromycin 
modulates the proliferation of antigen-specific T cells and 
enhances the anti-M. avium activity mediated by IL-12 
(Ichiyama et al., 2001).
Clarithromycin affects cytokine production by 
dendritic cells and T cells by inhibiting IL-2 and IL-6 
production, suppressing B cell activation and improving 
the condition of patients with lung disease (Sugiyama et 
al., 2007). Furthermore, it increases production of IL-10, 
which inhibits the production of pro-inflammatory cyto-
kines such as IL-2, IL-8, and TNF-a. Similarly, Mukae et 
al. (2010) found that Pseudomomas aeruginosa infections 
change the functions of dendritic cells and that macrolides 
act as anti-inflammatory agents modulating the functions 
of these cells by reducing the production of IL-6, IL-12, 
and TNF-a.
Reduction of neutrophils in the patients’ airways also 
decreased the release of leukotriene B4 and granule en-
zymes such as β-glucuronidase, lysozyme, and hydrolase. 
It also resulted in ROS production, which can cause tissue 
injury (Diep et al., 2010). Thus, macrolides decrease the 
number of airway infections not only by their direct effects 
on bacteria, but also by their ability to reduce inflammation 
(Yanagihara et al., 1997).
Therefore, the macrolides’ antimicrobial activity 
added to their involvement with cytokine production and 
release may affect regulation of hematopoiesis. Indeed, 
hematopoiesis is mediated by a range of cytokines that 
promote changes in the production and release of blood 
cells from the bone marrow to the peripheral blood and 
hence to the tissues. The process depends on drug plasma 
concentration and dose regimen, which in turn affect the 
time course of drug action.
No statistical difference between phagocytosis in 
control cells and in rat cells treated with the drugs was ob-
served. The literature is controversial regarding the action 
of clarithromycin on the neutrophilic phagocytosis. While 
a report observed a decreased phagocytosis associated to 
the drug (Wenisch et al., 1996), other studies reported an 
increased activity (Roszkowski et al., 1990; Scaglione et 
al., 1993; Xu et al., 1995). Differences in methodology, 
the animal and human models used, the concentrations 
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of the drug in vivo and in vitro, the protocols, and dosage 
and administration may partially explain the differences 
reported by these studies (Labro, 2000). Before our study, 
no results on the effects of the two drugs (clarithromycin 
and clofazimine) over neutrophilic phagocytosis were 
available.
Our study provides some initial results on the ef-
fects that the use of these two drugs combined may have 
on the oxidative burst and on neutrophilic phagocytosis. 
Nevertheless we cannot say that these same results would 
be observed in patients taking these drugs. It is possible 
that different results could be found due to differences 
in the immune response while in an inflammatory envi-
ronment, which might be observed in studies done with 
disease models.
Because a combination of the two drugs has been 
indicated for the treatment of Leprosy (Declercq, 2001) 
and for the treatment of the infections caused by the 
Mycobacterium avim complex (Field, Cowie, 2003), its 
important to know how these two drugs act and what kind 
of side effects they may have. Our data may contribute to 
a better understanding of the effects of these two drugs 
when used to treat these diseases.
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